Risk of CMV reactivation based on clinical and laboratory parameters. (A) Major lymphocyte subsets in patients treated with letermovir after allo-HCT: ALC, CD3⁺CD4⁺CD8⁻ T cells (CD4), CD3⁺CD4⁻CD8⁺ T-cells (CD8), CD3⁻CD56⁺ NK cells, CD3⁻CD19⁺ B cells (CD19) are shown. There were no statistically significant differences between patients who experienced or those who did not experience csCMVi. (B) Pre-letermovir discontinuation IgG levels. ∗P < .05; ∗∗P < .005 (Wilcoxon rank-sum test).